The implications of this research are that because HTP exposure elicits damage at the cellular level, and because HTPs deliver less nicotine per puff, users could increase consumption and cumulative toxic exposure. HTPs should not be considered reduced-risk; regulatory oversight, clear public-health warnings, and further research on long-term effects are warranted.
Landwehr et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: